BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elfiky AA, Elshemey WM, Gawad WA, Desoky OS. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J 2013;32:75-80. [PMID: 23322006 DOI: 10.1007/s10930-013-9462-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Elfiky AA, Azzam EB. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective. J Biomol Struct Dyn 2021;39:2923-31. [PMID: 32306854 DOI: 10.1080/07391102.2020.1758789] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 12.5] [Reference Citation Analysis]
2 Elfiky AA, Ismail AM. Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor. Future Virology 2017;12:339-47. [DOI: 10.2217/fvl-2017-0027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
3 Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592. [PMID: 32222463 DOI: 10.1016/j.lfs.2020.117592] [Cited by in Crossref: 371] [Cited by in F6Publishing: 342] [Article Influence: 185.5] [Reference Citation Analysis]
4 Elfiky AA. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study. Med Chem 2019;15:130-7. [PMID: 30324891 DOI: 10.2174/1573406414666181015152511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6. [PMID: 28486403 DOI: 10.3390/biology6020030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
6 Ezat AA, El-Bialy NS, Mostafa HI, Ibrahim MA. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V). Protein J 2014;33:32-47. [PMID: 24374429 DOI: 10.1007/s10930-013-9538-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
7 Zia A, Abbasi SW, Ahmad S, Zia M, Raza A. Phylogenetic analysis, structure modeling and docking study of HCV NS3 protease for the identification of potent inhibitors. Infect Genet Evol 2018;59:51-62. [PMID: 29391202 DOI: 10.1016/j.meegid.2018.01.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ahmad Mir S, Firoz A, Alaidarous M, Alshehri B, Aziz Bin Dukhyil A, Banawas S, Alsagaby SA, Alturaiki W, Ahmad Bhat G, Kashoo F, Abdel-Hadi AM. Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals of Nigella sativa: An in silico approach. Saudi J Biol Sci 2021. [PMID: 34518755 DOI: 10.1016/j.sjbs.2021.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Elfiky AA, Elshemey WM. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds. J Med Virol 2018;90:13-8. [PMID: 28922464 DOI: 10.1002/jmv.24934] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
10 Shiokawa M, Fukuhara T, Ono C, Yamamoto S, Okamoto T, Watanabe N, Wakita T, Matsuura Y. Novel permissive cell lines for complete propagation of hepatitis C virus. J Virol. 2014;88:5578-5594. [PMID: 24599999 DOI: 10.1128/JVI.03839-13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
11 Ganesan A, Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin Drug Discov 2017;12:407-25. [PMID: 28164720 DOI: 10.1080/17460441.2017.1291628] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
12 Elfiky AA, Ismail AM. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. SAR QSAR Environ Res 2018;29:409-18. [PMID: 29652194 DOI: 10.1080/1062936X.2018.1454981] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
13 Memon MS, Arain ZI, Naz F, Zaki M, Kumar S, Burney AA. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study. J Diabetes Res 2013;2013:539361. [PMID: 23984431 DOI: 10.1155/2013/539361] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
14 Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. [PMID: 32119961 DOI: 10.1016/j.lfs.2020.117477] [Cited by in Crossref: 305] [Cited by in F6Publishing: 290] [Article Influence: 152.5] [Reference Citation Analysis]
15 Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR. Blocking Zika virus vertical transmission. Sci Rep 2018;8:1218. [PMID: 29352135 DOI: 10.1038/s41598-018-19526-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
16 Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol 2017;89:1040-7. [PMID: 27864902 DOI: 10.1002/jmv.24736] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
17 Sinigaglia A, Riccetti S, Trevisan M, Barzon L. In silico approaches to Zika virus drug discovery. Expert Opin Drug Discov 2018;13:825-35. [PMID: 30160181 DOI: 10.1080/17460441.2018.1515909] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Noell BC, Besur SV, deLemos AS. Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther. 2015;9:2367-2374. [PMID: 25987834 DOI: 10.2147/dddt.s65255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
19 Elfiky AA. Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase. Future Virology 2017;12:721-8. [DOI: 10.2217/fvl-2017-0081] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
20 Pandey K, Lokhande KB, Swamy KV, Nagar S, Dake M. In Silico Exploration of Phytoconstituents From Phyllanthus emblica and Aegle marmelos as Potential Therapeutics Against SARS-CoV-2 RdRp. Bioinform Biol Insights 2021;15:11779322211027403. [PMID: 34248355 DOI: 10.1177/11779322211027403] [Reference Citation Analysis]
21 Elfiky AA, Ismail A. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life Sci 2019;238:116958. [PMID: 31628915 DOI: 10.1016/j.lfs.2019.116958] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
22 Ndako JA, Owolabi AO, Olisa JA, Akinwumi JA, Dojumo VT, Olatinsu O, Adebayo BA. Studies on the prevalence of Hepatitis C virus infection in diabetic patients attending a tertiary health-care facility South-west Nigeria. BMC Infect Dis 2020;20:664. [PMID: 32907538 DOI: 10.1186/s12879-020-05388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
24 Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol 2016;88:2044-51. [PMID: 27604059 DOI: 10.1002/jmv.24678] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
25 Elfiky AA, Elshemey WM. IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med Chem Res 2016;25:1005-8. [PMID: 32214769 DOI: 10.1007/s00044-016-1533-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
26 Tsai WL, Cheng JS, Liu PF, Chang TH, Sun WC, Chen WC, Shu CW. Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells. Aging (Albany NY) 2022;14. [PMID: 35833210 DOI: 10.18632/aging.204170] [Reference Citation Analysis]
27 Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K. Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evol 2016;2:vew024. [PMID: 27774307 DOI: 10.1093/ve/vew024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
28 Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn 2021;39:3204-12. [PMID: 32338164 DOI: 10.1080/07391102.2020.1761882] [Cited by in Crossref: 70] [Cited by in F6Publishing: 89] [Article Influence: 35.0] [Reference Citation Analysis]
29 Shen Z, Zhu X, Zhang H, Chen H, Niu J, Chen G, Li X, Ding Y. Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects. Clin Pharmacol Drug Dev 2019;8:1073-80. [PMID: 30900816 DOI: 10.1002/cpdd.674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Saad Y, Awad A, Alakel W, Doss W, Awad T, Mabrouk M. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients. Eur J Gastroenterol Hepatol 2018;30:201-6. [PMID: 29099423 DOI: 10.1097/MEG.0000000000001008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]